After cardiovascular disorders, cancer is the world 's second leading cause of mortality. The location of the cancer in the bodily organ determines the type of cancer. Different forms of cancer have different metabolic behaviors that are sometimes conflicting. Nonetheless, the oncogenic phenotype is supported by each cancer's unique metabolism. The immuno-biological microenvironments at distinct metastatic organ sites are major factors for variances in efficacy, and immunotherapy benefits a small proportion of patients across multiple cancer types. Recent advancements in cancer diagnosis and treatment, cancer survival has increased, and so there is a greater emphasis on quality rather than quantity of survival.
Title : RNA binding proteins in the pathogenesis of pediatric cancer
Atif A Ahmed, University of Washington-Seattle Children’s Hospital, United States
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title :
Jianhua Luo, University of Pittsburgh, United States
Title : Biosensor-based detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Principles of oral rehabilitation in H&N cancer patients
Pietro Salvatori, Independent H&N Surgeon, Italy
Title :
Marika Crohns, Impactful Innovations Management Consultants LLC, United Arab Emirates